» Articles » PMID: 31273200

Metabolomic Signature of Exposure and Response to Citalopram/escitalopram in Depressed Outpatients

Abstract

Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that are known to be influenced by human gut microbial cometabolism. 5HT, 5-hydroxyindoleacetate (5HIAA), and the ratio of 5HIAA/5HT showed significant correlations to temporal changes in HRSD scores. In the tyrosine pathway, changes were observed in the end products of the catecholamines, 3-methoxy-4-hydroxyphenylethyleneglycol and vinylmandelic acid. Furthermore, two phenolic acids, 4-hydroxyphenylacetic acid and 4-hydroxybenzoic acid, produced through noncanconical pathways, were increased with drug exposure. In the purine pathway, significant reductions in hypoxanthine and xanthine levels were observed. Examination of metabolite interactions through differential partial correlation networks revealed changes in guanosine-homogentisic acid and methionine-tyrosine interactions associated with HRSD. Genetic association studies using the ratios of these interacting pairs of metabolites highlighted two genetic loci harboring genes previously linked to depression, neurotransmission, or neurodegeneration. Overall, exposure to escitalopram/citalopram results in shifts in metabolism through noncanonical pathways, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms.

Citing Articles

The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.

You Z, Lan X, Wang C, Liu H, Li W, Mai S CNS Neurosci Ther. 2025; 31(3):e70324.

PMID: 40059071 PMC: 11890978. DOI: 10.1111/cns.70324.


Medication use is associated with distinct microbial features in anxiety and depression.

Dilmore A, Kuplicki R, McDonald D, Kumar M, Estaki M, Youngblut N Mol Psychiatry. 2025; .

PMID: 39794490 DOI: 10.1038/s41380-024-02857-2.


Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.

Moss L, Laudenslager M, Steffen K, Sockalingam S, Coughlin J Curr Obes Rep. 2025; 14(1):2.

PMID: 39753939 DOI: 10.1007/s13679-024-00598-5.


Finding the best predictive model for hypertensive depression in older adults based on machine learning and metabolomics research.

Guo J, Zhao J, Han P, Wu Y, Zheng K, Huang C Front Psychiatry. 2024; 15:1370602.

PMID: 38993388 PMC: 11236531. DOI: 10.3389/fpsyt.2024.1370602.


Mining key circadian biomarkers for major depressive disorder by integrating bioinformatics and machine learning.

Shi Y, Zhu J, Hou C, Li X, Tong Q Aging (Albany NY). 2024; 16(12):10299-10320.

PMID: 38874508 PMC: 11236317. DOI: 10.18632/aging.205930.


References
1.
Ji Y, Hebbring S, Zhu H, Jenkins G, Biernacka J, Snyder K . Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2010; 89(1):97-104. PMC: 3034442. DOI: 10.1038/clpt.2010.250. View

2.
Sallee M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S . The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel). 2014; 6(3):934-49. PMC: 3968369. DOI: 10.3390/toxins6030934. View

3.
Crismon M, Trivedi M, Pigott T, Rush A, Hirschfeld R, Kahn D . The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 1999; 60(3):142-56. View

4.
Ji Y, Biernacka J, Hebbring S, Chai Y, Jenkins G, Batzler A . Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. 2012; 13(5):456-63. PMC: 3941038. DOI: 10.1038/tpj.2012.32. View

5.
Liu D, Ray B, Neavin D, Zhang J, Athreya A, Biernacka J . Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Transl Psychiatry. 2018; 8(1):10. PMC: 5802574. DOI: 10.1038/s41398-017-0056-8. View